{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:52Z","timestamp":1792511932045,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The clinical presentation of varicella in unvaccinated persons, with skin vesicles and scabs, has facilitated the use of rapid diagnostic methods for confirming disease. Polymerase chain reaction (PCR) assays are the diagnostic method of choice. The sharp decline in unmodified cases of varicella due to the US varicella vaccination program has led to fewer healthcare providers being familiar with varicella presentation and an increased reliance on laboratory diagnosis to confirm suspected cases. The mild, atypical presentation of the disease in vaccinated persons (fewer skin lesions, mostly maculopapular) has made it more challenging for providers to recognize and also to collect samples to detect the virus. Nonetheless, PCR is highly sensitive and specific in confirming modified disease if adequate samples are provided. While a positive PCR result is confirmatory, interpreting a negative result can prove to be more challenging in determining whether suspected varicella is falsely negative or attributable to other causes. Enhanced education of healthcare providers is critical for adequate specimen collection from modified varicella cases. In addition, more sensitive commercial serologic assays are needed in the United States for varicella immunity testing in the vaccine era.<\/jats:p>","DOI":"10.1093\/infdis\/jiac363","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:12:49Z","timestamp":1666311169000},"page":"S450-S455","source":"Crossref","is-referenced-by-count":24,"title":["Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem"],"prefix":"10.1093","volume":"226","author":[{"given":"Sheila","family":"Dollard","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-hsin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lindstrom","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Marin","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Rota","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2022102100080333100_jiac363-B1","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2022102100080333100_jiac363-B2","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/jmv.10364","article-title":"Varicella in Americans from NHANES III: implications for control through routine immunization","volume":"70","author":"Kilgore","year":"2003","journal-title":"J Med Virol"},{"key":"2022102100080333100_jiac363-B3","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac221","article-title":"Monitoring varicella vaccine impact on varicella incidence in the United States: surveillance challenges and changing epidemiology, 1995\u20132019.","volume-title":"J Infect Dis","author":"Marin","year":"2022"},{"key":"2022102100080333100_jiac363-B4","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1086\/522150","article-title":"Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997\u20132005","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1128\/jcm.12.3.367-374.1980","article-title":"Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections","volume":"12","author":"Arvin","year":"1980","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0950268800029344","article-title":"Detection of specific IgM in varicella and herpes zoster by antibody-capture radioimmunoassay","volume":"101","author":"Kangro","year":"1988","journal-title":"Epidemiol Infect"},{"key":"2022102100080333100_jiac363-B7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jmv.1890080203","article-title":"Detection of antibody to varicella-zoster virus by competitive and IgM-antibody capture immunoassay","volume":"8","author":"Tedder","year":"1981","journal-title":"J Med Virol"},{"key":"2022102100080333100_jiac363-B8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/653113","article-title":"Evaluation of laboratory methods for diagnosis of varicella","volume":"51","author":"Leung","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022102100080333100_jiac363-B9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1001\/jama.1992.03490180073029","article-title":"Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection","volume":"268","author":"Nahass","year":"1992","journal-title":"JAMA"},{"key":"2022102100080333100_jiac363-B10","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1128\/JCM.06753-11","article-title":"Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review","volume":"50","author":"Wilson","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0732-8893(93)90075-I","article-title":"Comparison of MRC-5 and A-549 cells in conventional culture tubes and shell vial assays for the detection of varicella-zoster virus","volume":"17","author":"Brinker","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022102100080333100_jiac363-B12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archderm.1986.01660150060016","article-title":"A comparison of the Tzanck smear and viral isolation in varicella and herpes zoster","volume":"122","author":"Solomon","year":"1986","journal-title":"Arch Dermatol"},{"key":"2022102100080333100_jiac363-B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1346-8138.15619","article-title":"Detection of multinucleated giant cells in differentiated keratinocytes with herpes simplex virus and varicella zoster virus infections by modified Tzanck smear method","volume":"48","author":"Yamamoto","year":"2021","journal-title":"J Dermatol"},{"key":"2022102100080333100_jiac363-B14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0733-8635(18)30201-8","article-title":"Tests for detecting herpes simplex virus and varicella-zoster virus infections","volume":"12","author":"Cohen","year":"1994","journal-title":"Dermatol Clin"},{"key":"2022102100080333100_jiac363-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/09273949509069121","article-title":"American Uveitis Society Meeting, May 13, 1995 Fort Lauderdale, FL, USA","volume":"3","author":"Rosenbaum","year":"1995","journal-title":"Ocular Immunol Inflamm"},{"key":"2022102100080333100_jiac363-B16","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1128\/JCM.38.12.4315-4319.2000","article-title":"Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes","volume":"38","author":"Loparev","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B17","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1128\/JCM.00346-06","article-title":"Genotyping of varicella-zoster virus and the discrimination of Oka vaccine strains by TaqMan real-time PCR","volume":"44","author":"Parker","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/infdis\/jiq066","article-title":"Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine","volume":"203","author":"Pahud","year":"2011","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B19","first-page":"233","article-title":"Distribution of varicella-zoster virus strains carrying a PstI-site-less mutation in Japan and DNA change responsible for the mutation","volume":"59","author":"Hondo","year":"1989","journal-title":"Jpn J Exp Med"},{"key":"2022102100080333100_jiac363-B20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/jvi.66.2.1016-1020.1992","article-title":"Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates","volume":"66","author":"LaRussa","year":"1992","journal-title":"J Virol"},{"key":"2022102100080333100_jiac363-B21","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.1128\/JVI.76.22.11447-11459.2002","article-title":"Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus","volume":"76","author":"Gomi","year":"2002","journal-title":"J Virol"},{"key":"2022102100080333100_jiac363-B22","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1128\/JCM.38.9.3156-3160.2000","article-title":"Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR","volume":"38","author":"Loparev","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B23","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/CVI.05021-11","article-title":"Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions","volume":"18","author":"Thiele","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2022102100080333100_jiac363-B24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1128\/JCM.06630-11","article-title":"Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster","volume":"50","author":"Quinlivan","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2022102100080333100_jiac363-B25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.virol.2016.06.017","article-title":"Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites","volume":"496","author":"Jeon","year":"2016","journal-title":"Virology"},{"key":"2022102100080333100_jiac363-B26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0264-410X(96)00107-7","article-title":"Comparison of gpELISA and neutralizing antibody responses to Oka\/Merck live varicella vaccine (Varivax) in children and adults","volume":"15","author":"Krah","year":"1997","journal-title":"Vaccine"},{"key":"2022102100080333100_jiac363-B27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","article-title":"Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence","volume":"130","author":"Williams","year":"1974","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B28","first-page":"604","article-title":"Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"2022102100080333100_jiac363-B29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2022102100080333100_jiac363-B30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B31","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1086\/529448","article-title":"Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella","volume":"197","author":"Breuer","year":"2008","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/CMR.00031-09","article-title":"Impact of varicella vaccine on varicella-zoster virus dynamics","volume":"23","author":"Schmid","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2022102100080333100_jiac363-B33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/infdis\/139.4.432","article-title":"Complement-enhanced neutralizing antibody response to varicella-zoster virus","volume":"139","author":"Grose","year":"1979","journal-title":"J Infect Dis"},{"key":"2022102100080333100_jiac363-B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jcv.2013.01.015","article-title":"Varicella immunity in vaccinated healthcare workers","volume":"57","author":"Behrman","year":"2013","journal-title":"J Clin Virol"},{"key":"2022102100080333100_jiac363-B35","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1017\/S0950268816000595","article-title":"The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay","volume":"144","author":"Maple","year":"2016","journal-title":"Epidemiol Infect"},{"key":"2022102100080333100_jiac363-B36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00183-12","article-title":"Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test","volume":"19","author":"Sauerbrei","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"2022102100080333100_jiac363-B37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3349\/ymj.2014.55.2.459","article-title":"Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella","volume":"55","author":"Kim","year":"2014","journal-title":"Yonsei Med J"},{"key":"2022102100080333100_jiac363-B38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/vim.2017.0143","article-title":"Measles vaccine","volume":"31","author":"Griffin","year":"2018","journal-title":"Viral Immunol"},{"key":"2022102100080333100_jiac363-B39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jviromet.2017.11.011","article-title":"A novel cell-based high throughput assay to determine neutralizing antibody titers against circulating strains of rubella virus","volume":"252","author":"Kanbayashi","year":"2018","journal-title":"J Virol Methods"},{"key":"2022102100080333100_jiac363-B40","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1016\/j.vaccine.2018.08.010","article-title":"Rubella virus neutralizing antibody response after a third dose of measles\u2013mumps\u2013rubella vaccine in young adults","volume":"36","author":"McLean","year":"2018","journal-title":"Vaccine"},{"key":"2022102100080333100_jiac363-B41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/iai.12.3.606-613.1975","article-title":"Neutralizing antibody responses to varicella-zoster virus","volume":"12","author":"Schmidt","year":"1975","journal-title":"Infect Immun"},{"key":"2022102100080333100_jiac363-B42","doi-asserted-by":"crossref","first-page":"e00240-21","DOI":"10.1128\/JVI.00240-21","article-title":"Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J Virol"},{"key":"2022102100080333100_jiac363-B43","article-title":"Breadth and functionality of varicella-zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans","volume":"92(14):e00269-18","author":"Sullivan","year":"2018","journal-title":"J Virol"},{"key":"2022102100080333100_jiac363-B44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jmv.1890430204","article-title":"Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox","volume":"43","author":"Junker","year":"1994","journal-title":"J Med Virol"},{"key":"2022102100080333100_jiac363-B45","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.vaccine.2013.03.058","article-title":"Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients","volume":"31","author":"Prelog","year":"2013","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S450\/46582565\/jiac363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_4\/S450\/46582565\/jiac363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T08:33:34Z","timestamp":1676709214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/Supplement_4\/S450\/6764824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":45,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac363","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,21]]}}}